Dyadic International Posts Q1 Revenue Surge, Unveils New Biomanufacturing Partnerships
Dyadic International’s Q1 2026 earnings call highlighted a year-over-year revenue surge and outlined plans to expand its C1 enzyme production platform. Management also announced new strategic partnerships aimed at accelerating biomanufacturing scale-up in the second half of 2026.
1. Q1 2026 Earnings Call Overview
Dyadic International opened its Q1 2026 call by reporting a significant year-over-year increase in revenue, attributing growth to expanded licensing of its proprietary C1 enzyme platform. Management emphasized ongoing cost efficiencies and highlighted upcoming milestones tied to new strategic collaborations.
2. Strategic Partnerships and Scale-Up Plans
The company revealed partnerships with key biomanufacturing firms to scale C1 production for industrial applications, with pilot runs slated for mid-2026. Leadership noted these agreements aim to generate additional contract revenue and bolster the platform’s global adoption.
3. Outlook and Milestones
Dyadic reiterated its target to achieve further revenue growth in H2 2026 through expanded commercial deployments and tech transfers. The firm plans to report progress on scale-up and partnership rollouts in its Q2 update.